Cellectis S.A.
(NASDAQ: CLLS)
|
4:30 PM EDT, 04/26/24 | |||
---|---|---|---|---|
Last: $2.51 | Change: +0.02 | %Change: +0.63% | Volume: 223,279 |
Open: | $ 2.49 | Volume: | 223,279 | |
---|---|---|---|---|
High: | $ 2.51 | Yield(%) | 0.00 | |
Low: | $ 2.35 | P/E Ratio (ttm): | n/a | |
Dividend ($): | n/a | Market Cap ($): | 178.66M | |
EPS ($) | -1.68 | Shares Out: | 71.75M |
% Price Change (last 4 weeks): | -6.04 |
---|---|
% Price Change (last 13 weeks): | -9.78 |
% Price Change (last 26 weeks): | 147.76 |
% Price Change (last 52 weeks): | 28.35 |
% Price Change (year to date): | -19.16 |
Return on Equity (%): | -53.52 |
---|---|
Return on Assets (%): | -28.23 |
Return on Invested Capital (%): | -29.64 |
Gross Profit Margin (%): | 3.44 |
---|---|
Net Profit Margin (%): | -473.60 |
Operating Profit Margin (%): | -509.08 |
50-day Moving Average: | $2.62 |
---|---|
200-day Moving Average: | $2.40 |
Avg. Daily Vol. (last 50 days): | 40,986 |
Avg. Daily Vol. (last 200 days): | 638,094 |
52-wk high: | $3.77 |
52-wk low: | $0.96 |
Bid: | $2.40 |
Ask: | $2.70 |
Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.
|
Cellectis S.A.
8, rue de la Croix Jarry Paris IF 75013 Phone: 33.1.81.69.16.00 Fax: 33.1.81.69.16.06 http://www.cellectis.com |
Earnings (1year) ($): | -1.68 |
---|---|
Annual Dividend ($): | 0.00 |
Current P/E Ratio (ttm): | n/a |
Book Value ($): | 2.58 |
Cash Flow ($): | -1.92 |
Price/Earnings (x): | n/a |
---|---|
Price/Sales (x): | 4.99 |
Price/Book (x): | 0.81 |
Price/Cash Flow (x): | n/a |
Quick Ratio (x): | 2.54 |
---|---|
Current Ratio (x): | 2.54 |
LT Debt/Equity (x): | 53.34 |
Total Debt/Equity (x): | 64.23 |